Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Cancer Cell|September 23, 2014
TIPE3 is the transfer protein of lipid second messengers that promote cancerSvetlana A Fayngerts, Jianping Wu, Camilla L Oxley, et al.
Cancer Discovery|November 12, 2015
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven NeuroblastomaNicole R Infarinato, Jin H Park, Kateryna Krytska, et al.
Molecular Cell|July 4, 2020
Structural Insights into Pseudokinase Domains of Receptor Tyrosine KinasesJoshua B Sheetz, Sebastian Mathea, Hanna Karvonen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung AdenocarcinomaAnna Truini, Jacqueline H Starrett, Tyler Stewart, et al.
Molecular Cell|December 22, 2010
Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancerMaria Soledad Sosa, Cynthia Lopez-Haber, Chengfeng Yang, et al.
The EMBO Journal|April 23, 2004
Svp1p defines a family of phosphatidylinositol 3,5-bisphosphate effectorsStephen K Dove, Robert C Piper, Robert K McEwen, et al.
Science Translational Medicine|November 11, 2011
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastomaScott C Bresler, Andrew C Wood, Elizabeth A Haglund, et al.
Cancer Cell|December 18, 2014
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastomaScott C Bresler, Daniel A Weiser, Peter J Huwe, et al.
Cell Reports|December 20, 2023
Distinct interactions stabilize EGFR dimers and higher-order oligomers in cell membranesKrishna C Mudumbi, Eric A Burns, David J Schodt, et al.
FEBS Letters|March 26, 2002
Normalization of nomenclature for peptide motifs as ligands of modular protein domainsRein Aasland, Charles Abrams, Christophe Ampe, et al.
Pageof 12